AU783760B2 - Method for detecting, treating, and monitoring conditions associated with activation of the coagulation response - Google Patents
Method for detecting, treating, and monitoring conditions associated with activation of the coagulation response Download PDFInfo
- Publication number
- AU783760B2 AU783760B2 AU67690/00A AU6769000A AU783760B2 AU 783760 B2 AU783760 B2 AU 783760B2 AU 67690/00 A AU67690/00 A AU 67690/00A AU 6769000 A AU6769000 A AU 6769000A AU 783760 B2 AU783760 B2 AU 783760B2
- Authority
- AU
- Australia
- Prior art keywords
- blood
- tests
- thrombin
- activation
- fibrinogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000000034 method Methods 0.000 title claims description 52
- 230000015271 coagulation Effects 0.000 title claims description 48
- 238000005345 coagulation Methods 0.000 title claims description 48
- 230000004913 activation Effects 0.000 title claims description 46
- 230000004044 response Effects 0.000 title claims description 46
- 238000012544 monitoring process Methods 0.000 title description 3
- 239000008280 blood Substances 0.000 claims description 72
- 210000004369 blood Anatomy 0.000 claims description 72
- 108090000190 Thrombin Proteins 0.000 claims description 51
- 229960004072 thrombin Drugs 0.000 claims description 51
- 238000009534 blood test Methods 0.000 claims description 46
- 238000012360 testing method Methods 0.000 claims description 44
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical group CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 43
- 239000004019 antithrombin Substances 0.000 claims description 34
- 108010073651 fibrinmonomer Proteins 0.000 claims description 33
- 108010049003 Fibrinogen Proteins 0.000 claims description 30
- 102000008946 Fibrinogen Human genes 0.000 claims description 30
- 229940012952 fibrinogen Drugs 0.000 claims description 30
- 108010041201 prothrombin fragment 1 Proteins 0.000 claims description 27
- 230000010118 platelet activation Effects 0.000 claims description 23
- 230000002159 abnormal effect Effects 0.000 claims description 18
- 241000009298 Trigla lyra Species 0.000 claims 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 28
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 28
- 208000001640 Fibromyalgia Diseases 0.000 description 26
- 238000003556 assay Methods 0.000 description 19
- 239000003146 anticoagulant agent Substances 0.000 description 16
- 229940127219 anticoagulant drug Drugs 0.000 description 16
- 210000002889 endothelial cell Anatomy 0.000 description 15
- 238000002560 therapeutic procedure Methods 0.000 description 12
- 108010073385 Fibrin Proteins 0.000 description 10
- 102000009123 Fibrin Human genes 0.000 description 10
- 229950003499 fibrin Drugs 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 201000005665 thrombophilia Diseases 0.000 description 9
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 7
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 7
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 238000011084 recovery Methods 0.000 description 7
- 241000701027 Human herpesvirus 6 Species 0.000 description 6
- 229960002897 heparin Drugs 0.000 description 6
- 229920000669 heparin Polymers 0.000 description 6
- 230000031915 positive regulation of coagulation Effects 0.000 description 6
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 5
- 108010094028 Prothrombin Proteins 0.000 description 5
- 230000008021 deposition Effects 0.000 description 5
- 238000000151 deposition Methods 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 208000011580 syndromic disease Diseases 0.000 description 5
- 108090000672 Annexin A5 Proteins 0.000 description 4
- 102000004121 Annexin A5 Human genes 0.000 description 4
- 206010003805 Autism Diseases 0.000 description 4
- 208000020706 Autistic disease Diseases 0.000 description 4
- 241000701022 Cytomegalovirus Species 0.000 description 4
- 102100027378 Prothrombin Human genes 0.000 description 4
- 208000021386 Sjogren Syndrome Diseases 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000001736 capillary Anatomy 0.000 description 4
- 208000037976 chronic inflammation Diseases 0.000 description 4
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 201000006417 multiple sclerosis Diseases 0.000 description 4
- 229940039716 prothrombin Drugs 0.000 description 4
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 3
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 3
- 102100030802 Beta-2-glycoprotein 1 Human genes 0.000 description 3
- 101710180007 Beta-2-glycoprotein 1 Proteins 0.000 description 3
- 208000018737 Parkinson disease Diseases 0.000 description 3
- 101800004937 Protein C Proteins 0.000 description 3
- 102000017975 Protein C Human genes 0.000 description 3
- 101800001700 Saposin-D Proteins 0.000 description 3
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000006020 chronic inflammation Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000001605 fetal effect Effects 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 229960000856 protein c Drugs 0.000 description 3
- 108010047303 von Willebrand Factor Proteins 0.000 description 3
- 102100036537 von Willebrand factor Human genes 0.000 description 3
- 229960001134 von willebrand factor Drugs 0.000 description 3
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 3
- 229960005080 warfarin Drugs 0.000 description 3
- 101710085003 Alpha-tubulin N-acetyltransferase Proteins 0.000 description 2
- 101710085461 Alpha-tubulin N-acetyltransferase 1 Proteins 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 206010020608 Hypercoagulation Diseases 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 208000016604 Lyme disease Diseases 0.000 description 2
- 102100023472 P-selectin Human genes 0.000 description 2
- 102000013566 Plasminogen Human genes 0.000 description 2
- 108010051456 Plasminogen Proteins 0.000 description 2
- 208000031732 Post-Lyme Disease Syndrome Diseases 0.000 description 2
- 102100026966 Thrombomodulin Human genes 0.000 description 2
- 108010079274 Thrombomodulin Proteins 0.000 description 2
- 108010000499 Thromboplastin Proteins 0.000 description 2
- 102000002262 Thromboplastin Human genes 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 150000004775 coumarins Chemical class 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 108010091897 factor V Leiden Proteins 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 230000003480 fibrinolytic effect Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000003055 low molecular weight heparin Substances 0.000 description 2
- 229940127215 low-molecular weight heparin Drugs 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 230000007310 pathophysiology Effects 0.000 description 2
- 229940012957 plasmin Drugs 0.000 description 2
- 230000002947 procoagulating effect Effects 0.000 description 2
- 239000011241 protective layer Substances 0.000 description 2
- 108010014806 prothrombinase complex Proteins 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 206010043554 thrombocytopenia Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229960000187 tissue plasminogen activator Drugs 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 101800001401 Activation peptide Proteins 0.000 description 1
- 102400000069 Activation peptide Human genes 0.000 description 1
- 101710081722 Antitrypsin Proteins 0.000 description 1
- 102100040214 Apolipoprotein(a) Human genes 0.000 description 1
- 206010003178 Arterial thrombosis Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108090000201 Carboxypeptidase B2 Proteins 0.000 description 1
- 102100035023 Carboxypeptidase B2 Human genes 0.000 description 1
- 201000005019 Chlamydia pneumonia Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108010074864 Factor XI Proteins 0.000 description 1
- 108010071289 Factor XIII Proteins 0.000 description 1
- 208000001951 Fetal Death Diseases 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 208000008899 Habitual abortion Diseases 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 108090000481 Heparin Cofactor II Proteins 0.000 description 1
- 102100030500 Heparin cofactor 2 Human genes 0.000 description 1
- 229920001499 Heparinoid Polymers 0.000 description 1
- 101000622137 Homo sapiens P-selectin Proteins 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- 208000032420 Latent Infection Diseases 0.000 description 1
- 108010033266 Lipoprotein(a) Proteins 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 206010028570 Myelopathy Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 108010035766 P-Selectin Proteins 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 102000029301 Protein S Human genes 0.000 description 1
- 108010066124 Protein S Proteins 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 229940122388 Thrombin inhibitor Drugs 0.000 description 1
- 208000032109 Transient ischaemic attack Diseases 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000003429 anti-cardiolipin effect Effects 0.000 description 1
- 230000001475 anti-trypsic effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 108090001015 cancer procoagulant Proteins 0.000 description 1
- 210000001043 capillary endothelial cell Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 208000037771 disease arising from reactivation of latent virus Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 229940012444 factor xiii Drugs 0.000 description 1
- 231100000562 fetal loss Toxicity 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 239000002554 heparinoid Substances 0.000 description 1
- 229940025770 heparinoids Drugs 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 230000014508 negative regulation of coagulation Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 208000030773 pneumonia caused by chlamydia Diseases 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000003331 prothrombotic effect Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- -1 tPA Proteins 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000003868 thrombin inhibitor Substances 0.000 description 1
- 201000010875 transient cerebral ischemia Diseases 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000006439 vascular pathology Effects 0.000 description 1
- 210000004269 weibel-palade body Anatomy 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/22—Haematology
- G01N2800/224—Haemostasis or coagulation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/30—Psychoses; Psychiatry
- G01N2800/306—Chronic fatigue syndrome
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Materials For Medical Uses (AREA)
Description
WO 01/12839 PCT/US00/22177 METHOD FOR DETECTING, TREATING, AND MONITORING CONDITIONS ASSOCIATED WITH ACTIVATION OF THE COAGULATION RESPONSE FIELD OF THE INVENTION This Non-Provisional Application claims the benefit of U.S. Provisional Application Serial No. 60/148,799 filed on August 13, 1999. This invention relates to methods for detecting, treating, and monitoring conditions associated with activation of the coagulation response which respond to anti-coagulant therapy.
BACKGROUND OF THE INVENTION Chronic fatigue syndrome (CFS) and fibromyalgia (FM) have been considered diagnoses of exclusion where no other diagnosis fit well. CFS has been defined by specific requirements of fatigue, its duration, associated symptoms, and initial clinical and laboratory evaluation. There has existed no reliable laboratory means for determining whether an individual was suffering from CFS, FM, or some other disease. Accordingly, a felt need for a method of testing for CFS and FM existed.
SUMMARY OF THE INVENTION This invention relates to a method for using a novel combination of assays to detect minimal activation of the coagulation response for determining whether a patient whose initial clinical evaluation indicates chronic fatigue syndrome, fibromyalgia, and related conditions can be treated using anticoagulant therapies. If activation of the coagulation response is detected, the present invention further includes treatment of CFS, FM or related condition using anticoagulant therapies.
We have discovered that we may reliably diagnose a patient suffering from CFS or FM by evaluating the status of the coagulation response in that patient by using a novel 1 SUBSTITUTE SHEET (RULE 26) combination of tests which can detect minimal activation of the coagulation response in a patient. This novel combination preferably includes tests for determining levels of fibrinogen, prothrombin fragmentl 2, thrombin/antithrombin complexes, soluble fibrin monomer, and platelet activation by flow cytometry. These assays are preferred because they are highly sensitive to minimal deviation from normal. However, in some circumstances, other assays may be suitable. Deviation from the normal values in any two of the five assays permits diagnosis of CFS, FM, or other disease associated with activation of the coagulation response.
Accordingly, in one aspect the invention provides an ex vivo method for diagnosing a blood sample comprising steps of: identifying conditions that each cause a low level activation of the coagulation response in blood; providing a blood sample; providing different quantitative blood tests that are each for identifying low level activation of the coagulation response in blood; I>performing each of the different blood tests on the blood sample; and if at least two of the different blood tests identify low level activation of the coagulation response in the blood sample are abnormal, using the at least two of the blood tests to assist in diagnosing the blood sample with one of 20 the conditions.
The method may further comprise the steps of providing a population of blood samples, and performing the method for each of the blood samples of the population.
The different blood tests may comprise tests for at least two of fibrinogen, prothrombin fragment 1+2, thrombin/antithrombin complexes, and soluble fibrin monomer. Further, the different blood tests may comprise tests for at least three of fibrinogen, prothrombin fragment 1+2, thrombin/antithrombin complexes, and soluble fibrin monomer The different blood tests may comprise tests for at least two of fibrinogen, prothrombin fragment 1+2, thrombin/antithrombin complexes, soluble fibrin monomer, and platelet activation. Further, the different blood tests may comprise tests for at least three of fibrinogen, prothrombin fragment 1+2, thrombin/antithrombin complexes, soluble fibrin monomer, and platelet activation.
In the method, the different blood tests may comprise tests for fibrinogen, prothrombin fragment 1+2, thrombin/antithrombin complexes, soluble fibrin monomer, and platelet activation.
In another aspect, the invention provides an ex vivo method for diagnosing a blood sample comprising steps of: identifying a condition that causes low level activation of the coagulation response in blood; 15 providing a blood sample; providing different blood tests that are each for identifying low level activation of the coagulation response in blood; performing the different quantitative blood tests on the blood sample; and if at least two of the different blood tests identify low level activation of 20 the coagulation response in the blood sample, using the at least two of the blood tests to assist in diagnosing the blood sample with the condition.
The method may further comprise the steps of providing a population of blood samples and performing the method for each of the blood samples of the population.
The different blood tests may comprise tests for at least two of fibrinogen, prothrombin fragment 1+2, thrombin/antithrombin complexes, and soluble fibrin monomer. Further, the different blood tests may comprise tests for at least three of fibrinogen, prothrombin fragment 1+2, thrombin/antithrombin complexes, and soluble fibrin monomer The different blood tests may comprise tests for at least two of fibrinogen, prothrombin fragment 1+2, thrombin/antithrombin complexes, soluble fibrin monomer, and platelet activation. Further, the different blood tests may comprise tests for at least three of fibrinogen, prothrombin fragment 1+2, thrombin/antithrombin complexes, soluble fibrin monomer, and platelet activation.
In the method, the different blood tests may comprise tests for fibrinogen, prothrombin fragment 1+2, thrombin/antithrombin complexes, soluble fibrin monomer, and platelet activation.
In yet another aspect, the invention provides an ex vivo method for diagnosing a blood sample comprising steps of: identifying conditions that o 1 each cause a low level activation of the coagulation response in blood; providing a blood sample; providing different blood tests that are each for identifying low level activation of the coagulation response in blood, S: the blood tests comprising tests for at least two of fibrinogen, prothrombin fragment 1+2, thrombin/antithrombin complexes, soluble fibrin 20 monomer, and platelet activation; oo: obtaining a result for each of the blood tests; observing the results; and if at least two of the results are abnormal, using the abnormal results to assist in diagnosing the blood sample with one of the conditions.
The method may further comprise the steps of providing a population of blood samples, and performing the method for each of the blood samples of the population.
In yet another aspect, the invention provides an ex vivo method for diagnosing a blood sample comprising steps of: identifying a condition that causes a low level activation of the coagulation response in blood; providing a blood sample; providing different blood tests that are each for identifying low level activation of the coagulation response in blood; the blood tests comprising tests for fibrinogen, prothrombin fragment 1+2, thrombin/antithrombin complexes, soluble fibrin monomer, and platelet activation; and if at least two of the results are abnormal, using the abnormal results to assist in diagnosing the condition.
The method may further comprise the steps of providing a population of blood samples, and performing the method for each of the blood samples of the population.
Once a condition associated with activation of the coagulation response has been diagnosed, the patient is treated with anticoagulant therapy, such as heparin followed by warfarin or warfarin alone. Coumarins or coumarin derivatives may also be used. Heparin can be defined as heparin (porcine or bovine) or any of its derivatives, such as low molecular weight heparin (LMWH), oral heparin, heparinoids, or any other designer heparin-like drugs.
It is presently preferred that a low dose anticoagulant therapy be used. Patient progression and recovery is then monitored using the novel combination of assays.
We postulate that a majority of individuals diagnosed as CFS and/or FM on clinical criteria may be defined as having antiphospholipid antibody syndrome (APS) 25 with endothelial cells as a major disease target with or without platelet activation.
Laboratory findings in patients suffering with APS include anticardiolipin antibodies, lupus anticoagulants, antiphosphatidylserine antibodies, anti-B2GPI antibodies.
Clinical findings include thrombocytopenia, neurological complications, venous thrombosis, arterial thrombosis, and/or recurrent fetal loss. Patients with primary APS (PAPS) presently have no clinical or laboratory evidence of another definable autoimmune disease. Antiphospholipid antibodies WO 01/12839 PCTUS00/22177 have long been associated with a hypercoagulable state, involving both procoagulant activity as well as inhibition of anticoagulant and fibrinolytic activity. In CFS and/or FM patients, the principal antibodies found to date are the anti-B2GPI antibodies. This precedes the generation of a hypercoagulable state based on our proposed model.
Endothelial cells are protected in the microvascular circulation by B 2 GPI and Annexin V proteins. This protective layer helps endothelial cells maintain an anticoagulant environment. Exposure to pathogens, such as herpes viruses (HV, HHV6, EBV), cytomegalovirus (CMV), mycoplasma, chlamydia pneumonia, or some vaccines can result in both active persistent infection and latent infection in mononuclear and endothelial cells.
Some pathogens like CMV and HV constitutively express phosphatidylserine-like procoagulant activity, capable of binding Xa and Va to form the prothrombinase complex.
HHV6 is found in about 70% of all CFS patients. In several studies, this same 70% infection rate is seen in multiple sclerosis patients with HHV6. HHV6 is also implicated in chronic myelopathy. Endothelial cells serve as a reservoir for harboring HHV6. Infected endothelial cells lose the ability to synthesize prostacyclin with associated incapacity to deter platelet adhesion. In addition, CMV and HV express tissue factor antigen on each virus surface. HV can induce a prothrombotic phenotype in vascular endothelial cells. This phenotype markedly reduces heparin sulfate protcoglycan synthesis and surface expression by endothelial cells.
Thrombomodulin expression is also reduced in infected endothelium. Due to fibrin deposition, fibrinolysis activation may also be diminished. Activation of endothelial cells is seen by surface expression of P-selectin and von Willebrand Factor (vWF). Thrombin generated after the assembly of the prothrombinase complex on the virus-infected 3 SUBSTITUTE SHEET (RULE 26) WO 01/12839 PCTIUS00/22177 endothelium mobilizes vWF from the Weibel-Palade body to the endothelial cell surface, where it acts as a platelet receptor. Cell-independent thrombin generation may be the earliest event in vascular pathology mediated by HV.
Because exposure and expression of phosphatidylserine (PS) is part of the infectious process, those exposed phospholipids activate the immune system to form antiphospholipid antibodies. The primary targets of these immunoglobulin (Ig)G, IgM and IgA antibodies are the protective proteins for endothelial cells, specifically B2GPI and Annexin V. As with other APS diseases, there is an increased incidence of thrombocytopenia in HHV6 patients.
With the loss of this protective layer due to APL antibodies, coagulation proteins can bind, react and form thrombin If this process is not property inhibited (thrombin-antithrombin complexes), then excess thrombin can convert fibrinogen to soluble fibrin monomer (SFM). SFM is a sticky protein that increases blood viscosity and can coat endothelial cells surfaces as fibrin or fibrinoid material. Patients with CFS and FM symptoms typically have a hypercoagulable state demonstrated by increased markers of coagulation activation and increased blood viscosity due to the generation of soluble fibrin monomer (SFM). Once CFS and FM is diagnosed using our combination of assays, CFS/FM patients may be treated with anticoagulant therapies, and their treatment and recovery monitored using our combination of tests.
Patients with immune mediated chronic inflammatory disorders of many types can have low level activation of the coagulation response. Therefore, patients with a spectrum of chronic inflammatory processes may have low level activation of coagulation as part of their pathophysiology. We postulate that our tests for activation of the coagulation and platelet 4 SUBSTITUTE SHEET (RULE 26) WO 01/12839 PCT/US00/22177 systems also have application to other conditions which stem from activation of the coagulation response. This has been validated by preliminary studies of patients suffering with multiple sclerosis, breast implant sickness syndrome, fetal wastage syndrome, gulf war illness, inflammatory bowel disease, autism. As with CFS and FM, once diagnosed using our combination of assays, these patients may be treated with anticoagulant therapies, and their treatment and recovery monitored using our combination of tests.
We postulate that our combination of tests for detecting minimal activation of coagulation response also has application to detecting and treating, Sjogrens syndrome, late Lyme disease (also called chronic Lyme disease), transient ischemic attack, attention deficit disorder, Alzheimer's disease, Parkinson's disease, as well as some cardiovascular diseases.
Once diagnosed using our combination of assays, these patients should also benefit from treatment with anticoagulant therapies, and their treatment and recovery monitored using our combination of tests.
The Presently Preferred Assays Used To Determine Minimal Activation of Coagulation Response Although thrombin generation is among the first steps in the coagulation response, thrombin itself is difficult to quantify because it lasts only 30 seconds in the blood circulation.
Consequently, other measurable components of the coagulation response must be considered.
Prothrombin fragment 1+2, which is released when prothrombin is converted into thrombin, can be used to indicate activation of the coagulation response. Increased levels ofthrombin/antithrombin complexes (TATs) also indicate thrombin generation and an attempt to remove excess thrombin. Thus, an increased level of TATs also indicates activation of the coagulation response. When excess thrombin is generated by the SUBSTITUTE SHEET (RULE 26) WO 01/12839 PCT/US00/22177 coagulation response, fibrinogen is cleaved to soluble fibrin monomer (SFM). Accordingly, increased levels of SFM also indicate activation of the coagulation response. With the consumption offibrinogen, the body may compensate by increasing fibrinogen levels slightly above the normal range; therefore, increased fibrinogen levels are also an indicator of activation of the coagulation response. Finally, platelet activation may also be used as an indicator of coagulation response activation.
The tests discussed above are the assays presently preferred, it being understood that other tests sensitive to minimal activation of the coagulation response may be substituted for the assays discussed.
DETAILED DESCRIPTION OF THE INVENTION For the purposes of describing the invention, we discuss the form of the method of the present invention which is presently preferred; it being understood, however, that this invention is not limited to the precise arrangements, instrumentalities, and assays discussed.
Our new method for diagnosing CFS, FM, and related conditions uses a novel combination of assays for detecting minimal activation of the coagulation response. Highly sensitive tests are used which are capable of detecting minimal deviations from normal levels offibrinogen, prothrombin fragment 1 2, thrombin/antithrombin complexes, soluble fibrin monomer, and platelet activation by flow cytometry, platelet aggregation, or related techniques. According to our invention, if a patient receives an initial clinical evaluation indicating CFS and/or FM and if 2 or more of the above assays show abnormal results, that patient can be reliably diagnosed with CFS and/or FM. Once a condition has been diagnosed that is responsive to anti-coagulant therapy, the patient is treated with low dose anticoagulant 6 SUBSTITUTE SHEET (RULE 26) WO 01/12839 PCT/US00/22177 therapy, such as heparin followed by warfarin, or pharmacologically and conceptually similar anticoagulant regimens. Patient progression and recovery is then monitored using the novel combination of assays.
In order to test our method, we have conducted a blinded study of 54 CFS and/or FM patients and 23 controls, for a total of 77 individuals. According to our method, blood drawn from all individuals was subjected to each of the 5 tests. Using our presently preferred combination of 5 assays, we determined that the CFS and FM patients could be reliably distinguished from the controls. Individuals whose blood tested outside of the normal range for 2 or more of the 5 tests were diagnosed as suffering from CFS and/or FM. 22 of the 23 controls were correctly identified. One control was positive in two assays for a false positivity rate of Of the 54 patients with CFS or FM, 4 had normal values, for a false negative rate of This shows that 92+% of CFS and/or FM patients had a demonstrable hypercoagulable state.
The following table sets out the mean values for each group tested.
7 SUBSTITUTE SHEET (RULE 26) WO 01/12839 PCT/US00/22177 TESTS: FIB mg/dl F1+2 nM T/AT ug/1 SFM nmol/i PA (Platelet CD62P% Activation) Reference Normal <310 <1.1 1.0-4.1 <20 Normal <26 Range Controls 23 280 1.0. 1.6 10 0% Positive 17.5 #Abnormal 2/23 3/23 4/23 3/23 0/23 5/23 /Normal Patients 54 367 1.2 1.6 22 42% Positive 22 #Abnormal 45/54 26/54 25/54 32/54 22/54 21/52 /Normal P Value <0.001 <0.005 <0.025 <0.001 <0.001 <0.10 As stated above, in CFS and FM patients, the principal antibodies found to date are the anti-B2GPI antibodies. Anti-B2GPI antibodies can precede the generation of a hypercoagulable state. In a normal capillary endothelial cell, phosphatidylserine is on the inside of the cell membrane. When phosphatidylserine is transported to the surface of the endothelial cell, it is isolated from blood flowing through the vessels by a layer of B2GPI and Annexin V proteins, which cover the phosphatidylserine. When the immune system is activated, anti-B2GPI and anti-annexin V antibodies, collectively antiphospholipid antibodies, are generated. These antibodies are IgG, IgA, and IgM, the majority of which bind to the B2GPI and annexin V proteins dislodging them from the phosphatidylserine. When the phosphatidylserine on the vessel walls is exposed, coagulation factor tenase and prothrombinase complexes bind to the surfaces of the endothelial cells which coat the vessel walls. When prothrombin complexes bind to the cell walls, prothrombin is converted to thrombin, which releases the activation peptide prothrombin fragment 1 2.
The human body responds to the generation of excess or inappropriate thrombin levels by synthesizing the inhibitor antithrombin. Antithrombin combines with thrombin to form thrombin/antithrombin complexes, which are then removed from the blood.
8 SUBSTITUTE SHEET (RULE 26) WO 01/12839 PCT/US00/22177 Antithrombin is a slow inhibitor of thrombin, but in the presence of heparin, antithrombin reacts with thrombin at a greatly increased rate. Activated protein C/antitrypsin complex is a secondary inhibitor of thrombin generation.
When more thrombin is generated than can be removed by the thrombin inhibitors, thrombin reacts with fibrinogen to create an intermediate protein called soluble fibrin monomer. Soluble fibrin monomer is a sticky protein which increases blood viscosity and forms deposits on capillary wall endothelial cells. The soluble fibrin monomer which is deposited on the capillary walls, a phenomenon called fibrin deposition, may block the passage of nutrients through the capillary walls to the surrounding tissues, whether it is another capillary, muscle or organ tissue. We postulate that the increase in blood viscosity in combination with associated blockage in nutrient transfer results in the fatigue of CFS and the muscle pain of FM. This could also be part of the explanation (pathology) of fetal demise and spontaneous abortions seen in recurrent miscarriages (fetal wastage syndrome).
In addition to the creation of soluble fibrin monomer, thrombin also activates factor XIII to XIIla in the blood, causing it to react with the soluble fibrin monomer to create insoluble fibrin strands, which may in turn generate a clot or fibrin deposition on vascular walls, further inhibiting blood flow and nutrient transfer. Once fibrin deposition or blood clot formation occurs, it becomes necessary to dissolve the fibrin. Protein C, which is activated by the excess thrombin production, helps to activate the fibrinolytic system when tissue plasminogen activator converts the protein plasminogen into plasmin. Plasmin is a very potent enzyme for fibrin depositions or clots and keeps the circulatory system of blood vessels open and clean. Tissue plasminogen activator is conventionally injected into patients 9 SUBSTITUTE SHEET (RULE 26) WO 01/12839 PCT/US00/22177 to dissolve blood clots, such as heart attacks, myocardial infarctions, strokes, blood clots in the eye, etc.
Platelet activation within the blood is also a contributing factor in thrombin formation.
Platelet activation reinforces the generation of thrombin by providing a major surface for thrombin formation. Platelets may be directly activated by the immune system when immunoglobulins activate glycoprotein receptors and cause platelets to become "sticky".
This "sticky state" can result in fibrin formation, vascular and endothelial cell changes, and, at times, platelet clumping. Platelet activation can be measured by a special laboratory procedure called flow cytometry, platelet aggregation or related techniques.
Differences in genetic makeup are the most likely reason that all people exposed to an immune system activating pathogen do not develop diseases associated with a hypercoagulable state, such as chronic fatigue syndrome and fibromyalgia. Patients who have a hereditary deficiency for thrombophilia or hypofibrinolysis may be unable to properly control thrombin generation. Genetic defects in the proteins which regulate the coagulation process, are most likely the cause of long term activation of the immune system which results in a persistent hypercoagulable state. Thrombophilia may be caused by one or more genetic abnormalities in proteins which presently include protein C, protein S, antithrombin, factor V leiden, factor II gene mutation, thrombomodulin, heparin cofactor II, or factors II, VII, IX, X, XI, XII, and others which may be found for related genes. Hypofibrinolysis may be caused by one or more genetic abnormalities factors which presently include plasminogen, tPA, urokinase, PA-1, lipoprotein(a), homocysteine, factor V leiden, factor XI, and TAFI, and others which may be found for related genes.
SUBSTITUTE SHEET (RULE 26) WO 01/12839 PCT/US00/22177 Patients with immune mediated chronic inflammatory disorders of many types can have low level activation of the coagulation response. Therefore, patients with a spectrum of chronic inflammatory processes may have low level activation of coagulation as part of their pathophysiology. We postulate that our tests for activation of the coagulation and platelet systems also have application to other conditions which stem from activation of the coagulation response. This has been validated by preliminary studies of patients suffering with multiple sclerosis, breast implant sickness syndrome, gulf war illness, inflammatory bowel disease, autism, and fetal wastage syndrome. As with CFS and FM, once diagnosed using our combination of assays, these patients may be treated with anticoagulant therapies, and their treatment and recovery monitored using our combination of tests. We propose that a common feature of these conditions is the chronic inflammatory process that stimulates low level activation of coagulation.
The following table sets out our preliminary findings for autism, attention deficit disorder, multiple sclerosis, Parkinson's disease, Sjogrens syndrome, and gulf war illness.
Individuals who were diagnosed as suffering from one of these chronic inflammatory disorders tested outside of the normal range for 2 or more of the 5 tests in our method.
11 SUBSTITUTE SHEET (RULE 26) WO 01/12839 PTUOI2 PCT/USOO/22177 Disease TESTS Number of FEB mgtdl FI+2 T/AT SFM% PA Individuials tiM ugA nmo/1 (Platelet Tested Autism 3 #Abnormal 1/3 3/3 0/3 3/3 0/3 Attention 2 Deficit #Abnormal V21/2 1/2 V20/2 Disorder Multiple 3 Sclerosis #IAbnormal 1/3 1/3 2/3 2/3 0/3 Normal Parkinson's 2 Disease #Abnormal /21/2 V/2 0/2 0/2 Sjogrens I Disease #Abnormal 1/1 0/1 0/1 1/1 0/1 Nrml Gulf War 33 Illness #Abnormal 17/33 11/33 6/33 17/33 15/33 /Normal We postulate that our combination of tests for detecting minimal activation of coagulation response also has application to detecting and treating other immune mediated chronic inflammatory disorders such as Sjogrens syndrome, late Lyme disease (also called chronic Lyme disease), transient ischem-:ic attack, attention deficit disorder, Alzheimer's disease, Parkinson's disease, as well as some cardiovascular diseases. Once diagnosed using our combination of assays, these patients should also benefit from treatment with anticoagulant therapies, and their treatment and recovery monitored using our combination of tests.
12 SUBSTITUTE SHEET (RULE 26) It is to be understood that the words "comprise", "comprises", "comprising", "comprised" or the like, when used in this specification, are to be given a nonexhaustive meaning.
o* o o oo
Claims (19)
1. An ex vivo method for diagnosing a blood sample comprising steps of: identifying conditions that each cause a low level activation of the coagulation response in blood; providing a blood sample; providing different quantitative blood tests that are each for identifying low level activation of the coagulation response in blood; performing each of the different blood tests on the blood sample; and if at least two of the different blood tests identify low level activation of the coagulation response in the blood sample are abnormal, using the at o least two of the blood tests to assist in diagnosing the blood sample with one of the conditions.
2. The method of claim 1, further comprising the steps of providing a population of blood samples, and performing the method of claim 1 for each of the blood samples of the population.
G* The method of claim 1, wherein the different blood tests comprise tests for at least two of fibrinogen, prothrombin fragment 1+2, *thrombin/antithrombin complexes, and soluble fibrin monomer.
4. The method of claim 1, wherein the different blood tests comprise tests for at least three of fibrinogen, prothrombin fragment 1+2, thrombin/antithrombin complexes, and soluble fibrin monomer.
The method of claim 1, wherein the different blood tests comprise tests for at least two of fibrinogen, prothrombin fragment 1+2, thrombin/antithrombin complexes, soluble fibrin monomer, and platelet activation.
6. The method of claim 1, wherein the different blood tests comprise tests for at least three of fibrinogen, prothrombin fragment 1+2, thrombin/antithrombin complexes, soluble fibrin monomer, and platelet activation.
7. The method of claim 1, wherein the different blood tests comprise tests for fibrinogen, prothrombin fragment 1+2, thrombin/antithrombin complexes, soluble fibrin monomer, and platelet activation.
8. An ex vivo method for diagnosing a blood sample comprising steps of: identifying a condition that causes low level activation of the o coagulation response in blood; providing a blood sample; providing different blood tests that are each for identifying low level activation of the coagulation response in blood; performing the different quantitative blood tests on the blood sample; and if at least two of the different blood tests identify low level activation of the coagulation response in the blood sample, using the at least two of the blood tests to assist in diagnosing the blood sample with the condition.
9. The method of claim 8 further comprising the steps of providing a population of blood samples and performing the method of claim 8 for each of the blood samples of the population.
The method of claim 8, wherein the different blood tests comprise tests for at least two of fibrinogen, prothrombin fragment 1+2, thrombin/antithrombin complexes, and soluble fibrin monomer.
11. The method of claim 8, wherein the different blood tests comprise tests for at least three of fibrinogen, prothrombin fragment 1+2, thrombin/antithrombin complexes, and soluble fibrin monomer.
12. The method of claim 8, wherein the different blood tests comprise tests for at least two of fibrinogen, prothrombin fragment 1+2, thrombin/antithrombin complexes, soluble fibrin monomer, and platelet activation.
13. The method of claim 8, wherein the different blood tests comprise tests for at least three of fibrinogen, prothrombin fragment 1+2, thrombin/antithrombin complexes, soluble fibrin monomer, and platelet activation.
14. The method of claim 8, wherein the different blood tests comprise tests for fibrinogen, prothrombin fragment 1+2, thrombin/antithrombin complexes, soluble fibrin monomer, and platelet activation.
15. An ex vivo method for diagnosing a blood sample comprising steps of: identifying conditions that each cause a low level activation of the 1 coagulation response in blood; providing a blood sample; providing different blood tests that are each for identifying low level activation of the coagulation response in blood, the blood tests comprising tests for at least two of fibrinogen, prothrombin fragment 1+2, thrombin/antithrombin complexes, soluble fibrin monomer, and platelet activation; obtaining a result for each of the blood tests; observing the results; and if at least two of the results are abnormal, using the abnormal results to assist in diagnosing the blood sample with one of the conditions.
16. The method of claim 15 further comprising the steps of providing a population of blood samples, and performing the method of claim 15 for each of the blood samples of the population.
17. An ex vivo method for diagnosing a blood sample comprising steps of: identifying a condition that causes a low level activation of the coagulation response in blood; providing a blood sample; providing different blood tests that are each for identifying low level activation of the coagulation response in blood; the blood tests comprising tests for fibrinogen, prothrombin fragment 1+2, thrombin/antithrombin complexes, soluble fibrin monomer, and platelet activation; and if at least two of the results are abnormal, using the abnormal results to assist in diagnosing the condition. S
18. The method of claim 17 further comprising the steps of providing a ,o 9population of blood samples, and performing the method of claim 17 for each of the blood samples of the population. *SS•
19. A method as hereinbefore described, with reference to the examples. Dated this 2 0 th day of April 2005 David E. Berg, Lois Hill Berg and Harold H. Harrison by their Patent Attorneys Pipers Mills Oakley
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14879999P | 1999-08-13 | 1999-08-13 | |
| US60/148799 | 1999-08-13 | ||
| PCT/US2000/022177 WO2001012839A1 (en) | 1999-08-13 | 2000-08-11 | Method for detecting, treating, and monitoring conditions associated with activation of the coagulation response |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU6769000A AU6769000A (en) | 2001-03-13 |
| AU783760B2 true AU783760B2 (en) | 2005-12-01 |
Family
ID=22527442
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU67690/00A Ceased AU783760B2 (en) | 1999-08-13 | 2000-08-11 | Method for detecting, treating, and monitoring conditions associated with activation of the coagulation response |
Country Status (4)
| Country | Link |
|---|---|
| AU (1) | AU783760B2 (en) |
| CA (1) | CA2385502C (en) |
| GB (1) | GB2368642B (en) |
| WO (1) | WO2001012839A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030104493A1 (en) * | 2001-06-29 | 2003-06-05 | Ortel Thomas L. | Method for predicting an increased likelihood of antiphospholipid syndrome in a patient |
| JP2010271078A (en) * | 2009-05-19 | 2010-12-02 | Mcbi:Kk | Biomarker of mental disorder containing cognitive disorder, and method of detecting mental disorder containing cognitive disorder using biomarker |
| DE202022106913U1 (en) | 2022-12-09 | 2023-01-04 | Kusum Yadav | Cardiovascular disease detection system based on machine learning using IoT sensors |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5834215A (en) * | 1994-10-05 | 1998-11-10 | The Administrators Of The Tulane Educational Fund | Method for detecting antipolymer antibodies and diagnosing silicone related disease (SRD) fibromyalgia and chronic fatigue syndrome (CFS) |
| US5846758A (en) * | 1995-11-30 | 1998-12-08 | His Excellency Ghassan I. Shaker | Method for diagnosing autoimmune diseases |
-
2000
- 2000-08-11 CA CA2385502A patent/CA2385502C/en not_active Expired - Fee Related
- 2000-08-11 AU AU67690/00A patent/AU783760B2/en not_active Ceased
- 2000-08-11 GB GB0203838A patent/GB2368642B/en not_active Expired - Fee Related
- 2000-08-11 WO PCT/US2000/022177 patent/WO2001012839A1/en active IP Right Grant
Non-Patent Citations (3)
| Title |
|---|
| BERG D.E ET AL. (1997) BLOOD 90-SUPPL-(2): 111(B) ABST.3206 * |
| BONA R. ET AL. (1997) BLOOD 90-SUPPL-(2): 111(B) ABST. 3207 * |
| VECCHI, M ET AL. (1991) INT. J. CLIN LAB RES. 21: 165-170 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2385502A1 (en) | 2001-02-22 |
| WO2001012839A1 (en) | 2001-02-22 |
| GB2368642B (en) | 2004-07-07 |
| CA2385502C (en) | 2010-10-19 |
| GB2368642A (en) | 2002-05-08 |
| AU6769000A (en) | 2001-03-13 |
| GB0203838D0 (en) | 2002-04-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rehak et al. | The prevalence of activated protein C (APC) resistance and factor V Leiden is significantly higher in patients with retinal vein occlusion without general risk factors | |
| JP5882954B2 (en) | Methods and compositions for the treatment of persistent infection and cancer by inhibiting the programmed cell death 1 (PD-1) pathway | |
| US20060088532A1 (en) | Lymphatic and blood endothelial cell genes | |
| Kuhli-Hattenbach et al. | Coagulation disorders and the risk of retinal vein occlusion | |
| Carruthers et al. | The human erythrocyte sugar transporter is also a nucleotide binding protein | |
| JP6389122B2 (en) | Method for monitoring responsiveness to anti-SMAD7 therapy | |
| US20050255458A1 (en) | Drug discovery assays based on the biology of chronic disease | |
| Berg et al. | Chronic fatigue syndrome and/or fibromyalgia as a variation of antiphospholipid antibody syndrome: an explanatory model and approach to laboratory diagnosis | |
| Janion-Sadowska et al. | Plasma fibrin clot properties in the G20210A prothrombin mutation carriers following venous thromboembolism: the effect of rivaroxaban | |
| US6692969B1 (en) | Method for detecting, treating, and monitoring conditions associated with activation of the coagulation response | |
| Braun et al. | Accelerated atherosclerosis is independent of feeding high fat diet in systemic lupus erythematosus–susceptible LDLr−/− mice | |
| AU783760B2 (en) | Method for detecting, treating, and monitoring conditions associated with activation of the coagulation response | |
| Vicente et al. | Coagulation abnormalities in patients with Mediterranean spotted fever | |
| WO2003028627A2 (en) | Method for detecting procoagulant conditions | |
| Lang et al. | Prothrombotic activation of pulmonary arterial endothelial cells in a patient with tuberculosis | |
| Molinas et al. | Studies of blood coagulation and pathology in experimental infection of guinea pigs with Junin virus | |
| AU2002341736A1 (en) | Method for detecting procoagulant conditions | |
| Bossavy et al. | A new method for quantifying platelet deposition in flowing native blood in an ex vivo model of human thrombogenesis | |
| Hillis et al. | The expression of β1 integrins in human coronary artery | |
| Hoerl et al. | The diagnosis and clinical manifestations of activated protein C resistance: a case report and review of the literature | |
| Pinsky | Immune balance in critically ill patients | |
| WO2012065009A1 (en) | Ratio of apoa2 to hdlc or equivalents thereof, risk markers for cardiovascular disease | |
| Nagy et al. | Leiden mutation in patients with Crohn’s disease | |
| COLTEN¹ et al. | Allergy Division, Department of Medicine, Children's Hospital Medical Center, The Center for Blood Research, and the Department of Pediatrics, Harvard Medical School, Boston, Massachusetts | |
| NZ719884B2 (en) | Methods for monitoring responsiveness to anti-SMAD7 therapy |